Search Results
Your search for ASCO,ASCO matches 21309 pages
Showing 15401 - 15450Corporate Angel Network’s 50,000th Patient Flight Benefits Young Retinoblastoma Patient
On April 14, 2016, an 18-month-old patient with cancer named Baron Yerby flew home to Atlanta after receiving treatment at Memorial Sloan Kettering Cancer Center. However, instead of flying on a crowded commercial plane with the potential for immune deficiency issues, he and his parents flew on a...
The Parker Foundation Launches the Parker Institute for Cancer Immunotherapy With a $250 Million Grant
On April 13, The Parker Foundation announced a $250 million grant to launch the Parker Institute for Cancer Immunotherapy, a collaboration between scientists, clinicians, and industry partners to lead an unprecedented cancer immunotherapy research effort. The gift is the largest single contribution ...
A History of Medical Care for the Dying
In 2006, palliative care became a board-certified subspecialty of internal medicine, with specialized fellowships for physicians interested in the field. Despite its formal integration into best practices medical care, about 70% of Americans describe themselves as “not at all knowledgeable” about ...
Inspirational Stories for Cancer Survivors
Surveys indicate that cancer survivors have varying desires regarding the kind of support they want. Some patients find support groups very helpful as they deal with the host of issues in survivorship. Others want to distance themselves from the “world of cancer.” Studies also show that...
FDA Launches First Campaign Focused on Dangers of Smokeless Tobacco Among Rural Teens
The U.S. Food and Drug Administration (FDA) has announced it is expanding its award-winning “The Real Cost” campaign to educate rural white male teenagers about the negative health consequences associated with smokeless tobacco use. For the first time, messages on the dangers of smokeless tobacco...
2016 Oncology Meetings
MAY Lymphoma: State-of-the-Art in Biology Therapy, and Patient CareMay 13-14 • New York, New YorkFor more information: msklymphoma2016.com NCI “Sandpit” on Individual and Contextual Factors of Population-Level Cancer ControlMay 16-18 • Montgomery County, MarylandFor more...
Sixteen Leaders in Breast Cancer Research Join Susan G. Komen as Advisors
Susan G. Komen recently welcomed 16 leaders in breast cancer research and advocacy who will serve as Komen Scholars—an international advisory group that helps to guide Komen’s research and scientific programs, education and advocacy work, and public health efforts in the United States and abroad....
Chief Research Officer Named at the Pancreatic Cancer Action Network
The Pancreatic Cancer Action Network has announced Lynn Matrisian, PhD, MBA, as inaugural Chief Research Officer for the organization. Dr. Matrisian was promoted from Vice President of Scientific and Medical Affairs, where she has served since 2011. “To meet our aggressive goal to double survival...
Expert Point of View: Julie Margenthaler, MD and Mahmoud El-Tamer, MD
Press briefing moderator Julie Margenthaler, MD, of Washington University Siteman Cancer Center, St. Louis, who is Communications Committee Chair for the American Society of Breast Surgeons, agreed that surveillance would be acceptable only within a clinical trial, and one is underway now....
Sheldon M. Feldman, MD, Named President of ASBrS
Sheldon M. Feldman, MD, was named President of the American Society of Breast Surgeons (ASBrS) at the organization’s 2016 Annual Meeting in Dallas, Texas. Dr. Feldman is the Chief of Breast Surgery at NewYork-Presbyterian/Columbia University Medical Center and the Vivian L. Milstein Associate...
AUA 2016: Cell-Cycle Progression Score Provides Significant Prognostic Information in Patients With Gleason Score < 7
Myriad Genetics announced results from a study of the prognostic information provided by its Prolaris test in patients with prostate cancer and a Gleason score < 7 at the 111th Annual Scientific Meeting of the American Urological Association (AUA) (Abstract MP02-20). Prolaris is a novel 46-gene ...
ASH Meets With Officials, Provides Recommendations for the National Cancer Moonshot Initiative
On April 26, 2016, American Society of Hematology (ASH) President Charles S. Abrams, MD, shared the following statement: “Today ASH met with the White House to share scientific recommendations for the National Cancer Moonshot, an initiative spearheaded by Vice President Joe Biden that aims to make...
Tell Your Patients About PRE-ACT
Preparatory Education About Clinical Trials (PRE-ACT), a free video-based program, helps patients and their caregivers learn about clinical trials and address barriers to participation. Direct your patients to cancer.net/preact to learn more about this online resource. Also, visit cancer.net/blog...
Shop to Conquer Cancer!
ASCO Annual Meeting attendees have a special opportunity to support the Conquer Cancer Foundation (CCF) when you shop with any CCF retail partner during your stay in Chicago. When presented with the Conquer Cancer Card, participating retailers will donate a portion of sales from purchases made...
AUA 2016: BRCA Gene Mutations Associated With Increased Prostate Cancer Risk
Though predominantly known for their increased associations with breast cancer risk, germline mutations in the BRCA1 and BRCA2 genes are also associated with an increased susceptibility to other diseases, including prostate cancer. New data being presented during the 111th Annual Scientific Meeting ...
Redesigned ASCO.org Launches With Improved Usability
ASCO launched a new and improved website in early April, with a focus on improving the user experience. The Society’s redesigned online home makes it easier than ever for members and visitors to find the oncology-related information and resources they trust and value. The site’s redesign is the...
Interactive, Focused Learning at the ASCO Annual Meeting
The ASCO Annual Meeting, which will be held June 3–7, 2016, in Chicago, brings together more than 30,000 oncology professionals from around the world to learn about and discuss the latest therapies, treatment modalities, research, and controversies in the field. Attendees are able to personalize...
AUA 2016: Adjuvant Chemotherapy After Radical Prostatectomy May Benefit Men at High Risk for Relapse
Not all men with prostate cancer benefit from adjuvant chemotherapy after radical prostatectomy; however, African American men and men with a higher tumor stage may, according to a new U.S. Department of Veterans Affairs (VA) study (Abstract PI LBA 06) featured at the 111th Annual Scientific...
New JOP Articles Highlight the Impact of NCI Programs on Clinical Trial Enrollment
Two new original contributions in the Journal of Oncology Practice (JOP) highlight how National Cancer Institute (NCI) programs have impacted clinical trial enrollment. The first1 looked at the pilot phase of the NCI’s Community Cancer Centers Program (NCCCP) and found that trial availability and...
Donor Spotlight: Gateway for Cancer Research
The Conquer Cancer Foundation of ASCO is collaborating with Gateway for Cancer Research (Gateway) to fund a 2016 and 2017 Young Investigator Award through the Conquer Cancer Foundation Grants and Awards program. “Conquer Cancer Foundation is grateful for the generous support from Gateway and...
Shedding Light on a Cornucopia of Breast Tumor Biomarker Assays
As our understanding of the complexities of breast cancer expands, so does our treatment armamentarium—and along with it the range of factors that must be included in our treatment decisions. Gone is the simple algorithm of adjuvant chemotherapy for almost every patient with a ≥ 2-cm tumor, except...
ASCO Guideline on Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy in Early-Stage Invasive Breast Cancer
As reported in the Journal of Clinical Oncology by Lyndsay N. Harris, MD, and colleagues,1 ASCO has released a clinical practice guideline on the use of biomarkers in addition to estrogen receptor/progesterone receptor and HER2 status to guide decisions on adjuvant systemic therapy in women with...
Moving Forward in Castration-Resistant Prostate Cancer: The TERRAIN and STRIVE Studies
It was over 2 decades ago that my colleagues and I reported in The New England Journal of Medicine that a first-generation oral antiandrogen, flutamide, when added to a luteinizing hormone–releasing hormone (LHRH) agonist, improved survival by nearly 6 months compared to an LHRH agonist alone in...
Breaking Down Dogma With the Outgoing President of SGO
At the 2016 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer, The ASCO Post sat down with the SGO’s outgoing President, Robert L. Coleman, MD, and discussed the revolutionary potential of blood biomarkers, why enhanced recovery after surgery protocols is a significant...
Robert Weinberg, PhD, Receives AACR Award for Lifetime Achievement in Cancer Research
Robert Weinberg, PhD, was honored for his seminal contributions to cancer research and cancer biology with the 13th annual American Association for Cancer Research (AACR) Award for Lifetime Achievement in Cancer Research at the 2016 AACR Annual Meeting, held in New Orleans, April 16–20. The AACR...
Waun Ki Hong, MD, Receives 10th AACR Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research
The American Association for Cancer Research (AACR) honored Waun Ki Hong, MD, with the 10th annual Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research at the 2016 AACR Annual Meeting, held in New Orleans, April 16–20. The Margaret Foti Award for Leadership and...
FDA Approves Cabozantinib in Patients With Renal Cell Carcinoma Who Have Received Prior Antiangiogenic Therapy
On April 25, 2016, the U.S. Food and Drug Administration (FDA) approved cabozantinib (Cabometyx) tablets for the treatment of advanced renal cell carcinoma in patients who have received prior antiangiogenic therapy. Cabozantinib is a dual tyrosine kinase inhibitor of MET and VEGFR2. The capsule...
Roundup of Ovarian Cancer Abstracts From 2016 SGO Annual Meeting on Women’s Cancer
At the 2016 Society of Gynecologic Oncology’s (SOG’s) Annual Meeting on Women’s Cancer, Thomas J. Herzog, MD, Clinical Director, University of Cincinnati (UC) Cancer Institute and Professor of Obstetrics and Gynecology at UC College of Medicine, provided commentary on several noteworthy ovarian...
CancerCare Issues Report on Nationwide Surveys of 3,000 People Diagnosed With Cancer
The national nonprofit organization CancerCare has announced the publication of a comprehensive report on experiences, perceptions, and needs of people who are living with and beyond a cancer diagnosis. The 2016 CancerCare Patient Access and Engagement Report is a compilation of results from six...
Early Study Looks to Achieve Chloride Homeostasis Through Gene Transfer to Alleviate Cancer-Related Neuropathic Pain
A study providing new information about neuropathic pain afflicting some 90% of cancer patients who have had nerve damage caused by tumors, surgery, chemotherapy, or radiation indicates gene therapy as a possible treatment. The study in rats showed transfer of a gene known as KCC2 into the spinal...
Study Explores Differential Localization of Glioblastoma Subtypes and Pathogenesis
Researchers at the University of California San Diego School of Medicine have demonstrated that distinct types of glioblastoma tend to develop in different regions of the brain. This finding provides an explanation for how the same cancer-causing mutation can give rise to different types of brain...
Spectrin Gene Identified as a Biomarker in HPV-Negative Oral Cavity Squamous Cell Carcinoma
Researchers have identified a gene that may help to predict survival outcomes in patients with cancer of the mouth and tongue. Patients whose tumors express a gene called spectrin are 4.6 times more likely to die at any given time, according to a study by researchers at Loyola Medicine and Loyola...
Potential Targets for Loss of Appetite/Cachexia Related to Interleukin 18 Activity Identified in Early Studies
Loss of appetite during illness is a common and potentially debilitating phenomenon. In cancer patients especially, it can even shorten lifespan. Scientists at The Scripps Research Institute (TSRI) have discovered how an immune system molecule controls a brain circuit and reduces appetite. Their...
Assessing the Accuracy and Readability of Online Health Information for Patients With Pancreatic Cancer
Online information on pancreatic cancer overestimates the reading ability of the overall population and lacks accurate information about alternative therapy, according to a study published by Storino et al in JAMA Surgery. The degree to which patients are empowered by written educational materials ...
FDA Grants Priority Review for BLA for Olaratumab in Advanced Soft-Tissue Sarcoma
Eli Lilly and Company announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the biologics license application (BLA) for olaratumab, a platelet-derived growth factor receptor alpha (PDGFRα) antagonist, in combination with doxorubicin, for the...
FDA Grants sBLA for Blinatumomab in Pediatric Patients With Ph–Negative Relapsed/Refractory B-Cell Precursor ALL
Amgen announced on May 3 that the U.S. Food and Drug Administration (FDA) has accepted for priority review the supplemental Biologics License Application (sBLA) for blinatumomab (Blincyto) to include new data supporting the treatment of pediatric and adolescent patients with Philadelphia...
Effects of High Residential Segregation and Neighborhood Characteristics on Early-Stage NSCLC Surgery
Black residents of highly segregated neighborhoods were less likely to receive surgery for early-stage non–small cell lung cancer (NSCLC) than their peers in less-segregated neighborhoods, according to a study published by Johnson et al in Cancer Epidemiology, Biomarkers & Prevention....
ESTRO 2016: New Study Sheds Light on Mastectomy vs Breast-Conserving Therapy in Older vs Younger Patients With Early Breast Cancer
New research presented at the ESTRO 35 Conference on April 30 (Abstract OC-0052) has shown women aged younger than 45 years with early-stage breast cancer that had not spread to the lymph nodes and who opted for breast-conserving therapy with radiation therapy had a 13% higher risk of developing a...
ESTRO 2016: Radiotherapy vs Chemotherapy in a Study of Patients With Early Stage II Testicular Cancer
A large study of testicular cancer patients showed that radiation therapy was more effective than chemotherapy for patients with stage IIa disease (where one or more regional lymph nodes contain cancer cells, but they are less than 2 cm in diameter). These findings, presented at the ESTRO 35...
Study Finds Cancer Mortality Risks From Long-Term Exposure to Ambient Fine Particulate Matter
Long-term exposure to ambient fine particulate matter, a mixture of environmental pollutants, was associated with increased risk of mortality for many types of cancer in an elderly Hong Kong population, according to a study published by Wong et al in Cancer Epidemiology, Biomarkers &...
Tight Junction Protein 1 May Identify Sensitivity to Proteasome Inhibitors in Patients With Multiple Myeloma
A gene known as TJP1 (tight junction protein 1) could help determine which multiple myeloma patients would best benefit from proteasome inhibitors such as bortezomib, as well as combination approaches to enhance proteasome inhibitor sensitivity, according to a study led by researchers from The...
ESTRO 2016: SBRT in Early-Stage Lung Cancer Linked to Increased Risk of Noncancer Deaths
Researchers have found that treating patients who have early-stage non–small cell lung cancer (NSCLC) with stereotactic body radiation therapy (SBRT) is associated with a small but increased risk of death from causes other than cancer, according to findings presented at the European Society...
ESTRO 2016: Radiation and L19-IL2 Immunotherapy Combination Shows Activity in Preclinical Models
Radiation therapy not only targets and destroys cancer cells, but also helps to activate the immune system against their future proliferation. However, this immune response is often not strong enough to be able to completely eradicate tumors, and even when it is, its effect is limited to the area...
ESTRO 2016: Failure to Publish Phase III Radiotherapy Trial Results Exposes Patients to Risks Without Providing Benefits for Others
Although the publication of results of clinical trials carried out in the United States within 12 months of their completion has been mandatory since 2007, a remarkably high number of phase III radiotherapy trials did not do so, according to new research presented at the European Society for...
Study Links Residential Radon Exposure to Increased Risk of Hematologic Malignancies in Women
A new report published by Teras et al in Environmental Researchfound a statistically significant, positive association between high levels of residential radon and the risk of hematologic cancer (lymphoma, myeloma, and leukemia) in women. The study is the first prospective, population-based study...
Study Finds No Association Between Anthracycline-Based Chemotherapy and Cognitive Decline in Women With Breast Cancer
A new study by University of California, Los Angeles (UCLA) researchers published by Van Dyk et al in JAMA Oncology found that commonly used chemotherapy drugs showed no association with cognitive decline following treatment in women with breast cancer. The report addresses recent concerns that the ...
Cancer Screening Using Digital Mammography Alone or With Tomosynthesis in Varying Breast Densities
In a study published by Rafferty et al in JAMA, Elizabeth A. Rafferty, MD, formerly of Massachusetts General Hospital, and colleagues evaluated the screening performance of digital mammography combined with tomosynthesis compared with digital mammography alone for women with varying levels of...
Poor Understandability of Dense Breast Notifications Sent to Women Following Screening Mammography
In a study published by Kressin et al in JAMA, Nancy R. Kressin, PhD, of the Veterans Affairs Boston Healthcare System, Boston University School of Medicine, and colleagues examined the content, readability, and understandability of dense breast notifications sent to women following screening...
New Study Suggests Cholesterol Levels, Not Statins, Influence Colorectal Cancer Risk
Long-term use of the cholesterol-lowering drugs statins does not appear to decrease a patient’s risk of colorectal cancer, suggests a new, large case-control study from Penn Medicine published by Mamtani et al in PLOS Medicine. The observational analysis of over 100,000 patients’...
A Critical Analysis of Early Bladder Cancer Recurrence After Laparoscopic Radical Cystectomy
Although laparoscopic radical cystectomy and robotic-assisted radical cystectomy continue to grow in popularity and are successful in the treatment of bladder cancer, they are still considered experimental approaches. Using data collected by the Section of Uro-Technology of the European Association ...
